PedAM
Pediatric Disease Annotations & Medicines
| Disease | multicentric castleman disease |
| Phenotype | C0032285|pneumonia |
| Sentences | 1 |
| PubMedID- 20184247 | The patient received a humanized anti-interleukin-6 receptor antibody, (tocilizumab, 8 mg/kg), every 2 weeks for 3 years, during which time, his pao2 level improved from 64.1 torr to 83.4 torr, vital capacity increased from 2.53 l to 3.95 l, and radiological abnormalities in the lungs gradually improved, suggesting that tocilizumab is effective for interstitial pneumonia in patients with multicentric castleman disease. |
Page: 1